Introduction {#S1}
============

The lymphatic vasculature forms a network of blind-ended capillaries that collect protein rich fluid from the interstitial space and drain it via collecting vessels first into lymph nodes and then to larger lymphatic ducts, which connect to the venous system ([@R1]; [@R17]). The major functions of the lymphatic vasculature are to maintain tissue fluid balance, provide immune surveillance through transport of leukocytes and antigen-presenting dendritic cells and participate in fat absorption ([@R1]; [@R17]).

Congenital malformation of the lymphatic system such as vessel hypoplasia and valve defects cause primary lymphedema, which is usually a progressive and lifelong condition, characterized by gross swelling of the affected limb accompanied by fibrosis and susceptibility to infections ([@R1]; [@R17]). The management of symptoms is based on physiotherapy and compression garments as at present no effective treatment for lymphedema exists. Several genes, including *Vegfr3*, *Foxc2 and Sox18*, which were shown to regulate developmental lymphangiogenesis in mice ([@R11]; [@R19]; [@R33]), have been implicated in human lymphedema. Kinase inactivating mutations in the *VEGFR-3* gene lead to Milroy\'s disease ([@R7]), while mutations in the transcription factors *FOXC2* and *SOX18* are the underlying genetic causes of lymphedema-distichiasis and hypotrichosis-lymphedema-telangiectasia, respectively ([@R8]; [@R16]). Interestingly, defective luminal valves observed as a consequence of loss of *FOXC2* function ([@R33]) highlights the critical role of valves in maintaining unidirectional lymphatic flow. While the mechanisms of lymphatic valve morphogenesis remain poorly characterized, it has been well established that the interactions between the blood endothelial cells and their surrounding extracellular matrix (ECM), organized to facilitate valve function, are of key importance in regulating heart valve development and cardiac function, and consequently, heart valve disease ([@R2]; [@R25]). Similarly, ultrastructural analyses of lymphatic valves have demonstrated a close association between ECM and lymphatic endothelial cells in the valve leaflets ([@R21]; [@R30]). These findings suggest that the ECM has important functions in controlling endothelial cell signalling and could also provide structural integrity during lymphatic valve morphogenesis.

Cell-matrix adhesion receptors, such as integrins, play essential roles in developmental processes that involve close interactions between the cells and their surrounding ECM. Integrins are heterodimeric transmembrane receptors composed of α and β subunits. Their extracellular domains bind to the ECM molecules while the cytoplasmic domains associate with the actin cytoskeleton and affiliated proteins, thereby providing a link between the external and internal environment of the cell ([@R12]). In addition to mediating attachment to their respective ECM ligand(s), integrins have specialized signaling functions and they can regulate gene expression as well as cell shape, migration, proliferation and survival. Furthermore, integrin binding to ECM is not only required for transducing signals from the matrix to cells but this interaction also initiates responses that allow the cells to organize and remodel the matrix ([@R22]). Despite an apparent redundancy in their ligand-binding specificities, with several ECM molecules being ligands for more than one integrin, genetic studies have demonstrated distinct functions for individual integrins. Fibronectin (FN) receptors integrin-α5β1 and -α4β1, as well as components of the ECM, such as FN, play critical roles in the development of the blood vasculature ([@R15]). However, knowledge of the expression and function of integrins and the ECM in the lymphatic vasculature is limited ([@R4]).

Here we show that a member of the integrin-family, integrin-α9 (encoded by *Itga9*), was predominantly expressed in the endothelial cells of the lymphatic valve. Interestingly, *Itga9* deficiency in mice led to specific defects in the formation of luminal valves, which resulted in retrograde lymphatic flow and impaired fluid transport. We provide *in vivo* and *in vitro* evidence for the requirement of integrin-α9 interaction with its specific ligand, fibronectin-EIIIA (FN-EIIIA, also called EDA), in regulating FN matrix assembly and thereby identify an unexpected *in vivo* function for an integrin-EIIIA interaction. Collectively, our findings demonstrate an important role for integrin signaling in lymphatic valve development and provide novel insight into the previously undescribed morphogenetic process of lymphatic valve morphogenesis. As lymphatic valve defects manifested in adults are likely to have origins in valve development, integrin-α9 is a candidate gene for primary human lymphedema caused by lymphatic valve defects.

Results {#S2}
=======

Integrin-α9 is expressed in mature and developing lymphatic valves {#S3}
------------------------------------------------------------------

We surveyed expression of several integrins by immunofluorescence to determine which of these molecules might function during lymphatic valve formation. Whole-mount staining of adult skin using antibodies against specific α-subunits revealed low levels of integrin-α5 and -α6 expression in lymphatic endothelia and in the valve, while no apparent staining was detected using antibodies against integrin-α1, -α2 or -α4 (data not shown). In contrast, staining with integrin-α9 antibodies strongly highlighted the cells constituting the luminal valve ([Figures 1A and 1B](#F1){ref-type="fig"}). In agreement with previous studies ([@R14]), no integrin-α9 expression was detected in the blood vessel endothelia (data not shown).

Since integrin-α9 appeared to be the predominant α-subunit expressed in lymphatic endothelia and valves, we further characterized its expression pattern in developing vessels and aimed our study at determining its function in valve morphogenesis. During mouse development, the formation of valved collecting vessels occurs in late embryonic and early postnatal life through remodelling of a primitive lymphatic capillary network ([Figures 1C-1E](#F1){ref-type="fig"}; ([@R27]; [@R31])). At embryonic day (E)16, mesenteric lymphatic vessels form a vascular plexus that is LYVE-1 positive and does not contain valves ([Figures 1C and 1F](#F1){ref-type="fig"}). However, defined clusters of cells expressing high levels of Prox1 ([Figure 1F](#F1){ref-type="fig"}) and FoxC2 (data not shown) transcription factors are indicative of initiation of valve formation ([@R31]). At this stage integrin-α9 expression was low in lymphatic endothelia ([Figures 1F and 1G](#F1){ref-type="fig"}), while higher expression was detected in scattered cells in the surrounding tissue (data not shown) and in vascular SMCs around the blood vessels ([Figures 1F and 1G](#F1){ref-type="fig"}, arrowheads). At E17, the lymphatic vessels formed constrictions that showed elevated *Vegfr3*-lacZ reporter activity ([Figure 1D](#F1){ref-type="fig"}) and contained endothelial cells expressing high levels of FoxC2 ([Figure 1H](#F1){ref-type="fig"}), Prox1 (data not shown) and integrin-α9 ([Figures 1H and 1I](#F1){ref-type="fig"}). At E18, integrin-α9 was present in the endothelial cells of developed valve leaflets ([Figures 1J and 1K](#F1){ref-type="fig"}). Taken together, these expression data suggest that integrin-α9 upregulation in lymphatic endothelia correlated with the initiation of valve leaflet formation.

*Itga9* deficient mice display abnormal lymphatic valves {#S4}
--------------------------------------------------------

To investigate the physiological function of integrin-α9 in lymphatic valves we analysed *Itga9* deficient mice. These mice were reported to die perinatally of respiratory failure, caused by the presence of bilateral chylothorax ([@R14]), however the potential lymphatic vascular defects remained unknown. Analysis of chyle-filled mesenteric collecting vessels revealed characteristic V-shaped valves in wild-type neonates ([Figures 2A and 2A](#F2){ref-type="fig"}′). In contrast, *Itga9* mutant mice displayed fewer and morphologically abnormal valves ([Figures 2B and 2B](#F2){ref-type="fig"}′). Staining with an antibody against PECAM-1, which is strongly expressed in endothelial cells forming the valve leaflets ([Figure 2C](#F2){ref-type="fig"}), demonstrated that most of the mutant valves appeared as horizontal constrictions rather than V-shaped structures ([Figures 2D, 2E and 2F](#F2){ref-type="fig"}). Leakage of chylous fluid from the mesenteric vessels further indicated that they were dysfunctional (arrowhead in [Figure 2B](#F2){ref-type="fig"}). The defects in *Itga9* deficient mice were specific to lymphatic valves since we observed apparently normal development and gross morphology of the lymphatic vasculature in all tissues that were examined ([Figures S1A-S2H](#SD1){ref-type="supplementary-material"}).

Examination of longitudinal transmission electron microscopy sections of the valves of mesenteric lymphatic vessels revealed leaflets consisting of two endothelial layers with a central connective tissue core ([Figures 2G, 2I, 2K](#F2){ref-type="fig"}; ([@R21]; [@R30])). The endothelial cells of the wild-type valve leaflets formed long, overlapping cell-cell junctions, and they were tightly attached to the matrix core ([Figures 2G and 2I](#F2){ref-type="fig"}). In the *Itga9^-/-^* vessels the cusps of the valves were shorter with fewer endothelial cells ([Figures 2H and 2K](#F2){ref-type="fig"}). The disorganized or absent matrix core in between the basal sides of the endothelial cells was associated with the separation of the opposite endothelial surfaces ([Figure 2J](#F2){ref-type="fig"}). These results suggest that integrin-α9 function is essential for the formation of the defined ECM core of a valve leaflet.

Retrograde lymph flow and impaired fluid transport in *Itga9^-/-^* mice {#S5}
-----------------------------------------------------------------------

Luminal valves have an important role in establishing unidirectional lymphatic flow. To evaluate if lymphatic function is compromised in the *Itga9^-/-^* mice, we investigated uptake and transport of subcutaneously injected large-molecular-weight fluorescent dextran. In wild-type mice the FITC-dextran injected into the forelimb footpad was rapidly drained into the valved dermal collecting lymphatic vessels, which were visualized proximal to the injection site ([Figure 3A](#F3){ref-type="fig"}). In contrast, in the *Itga9* mutant skin the dye labeled a vessel network ([Figure 3B](#F3){ref-type="fig"}), suggesting retrograde lymphatic flow from the collecting vessels to the pre-collector vessel branches ([@R27]; [@R33]). In addition, the dye showed leakage into the surrounding tissue and the transport from the injection site to the lymph nodes and the thoracic duct was impaired ([Figures S2A-S2D](#SD1){ref-type="supplementary-material"}). We also analyzed the lymphatic drainage after subcutaneous injection of FITC-conjugated *Lycopersicum Esculentum* lectin (LEL), which binds to the surface of lymphatic endothelial cells, in particular in the valves ([@R42]) ([Figure 3C](#F3){ref-type="fig"}). In the *Itga9* mutants valve regions were identified by stronger lectin staining, however, the valves were abnormal and often lacked obvious leaflets ([Figures 3D and 3E](#F3){ref-type="fig"}). Together, the above data show that *Itga9* deficient mice display specific defects in valve morphogenesis, which result in retrograde lymphatic flow and impaired fluid transport.

Integrin-α9 is required tissue-autonomously in endothelia for lymphatic valve development {#S6}
-----------------------------------------------------------------------------------------

To examine if integrin-α9 has a tissue-autonomous function in lymphatic endothelia during valve development we deleted its expression specifically in endothelial cells by crossing the floxed *Itga9^lx^* mice ([@R37]) with *Tie2-Cre* animals ([@R20]). The homozygous *Tie2-Cre;Itga9^lx/lx^* mice displayed chylothorax (data not shown) and reduced number of lymphatic valves ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}). The few valves that were detected displayed abnormal leaflets, as visualized by staining for an ECM molecule Laminin-α5 ([Figures 4A-4D](#F4){ref-type="fig"}).

We next asked whether integrin-α9 is also essential for the maintenance of the valves. We used *VE-cadherin-CreER^T2^* mice, which allow tamoxifen-regulated activation of Cre in both blood and lymphatic endothelia (R. Adams, unpublished; [Figures S3C and S3D](#SD1){ref-type="supplementary-material"}). To induce *Itga9* gene deletion in mature valves, 4-hydroxytamoxifen (4-OHT) was injected into control *Itga9^lx/^*^+^ ([Figures 4E-4H](#F4){ref-type="fig"}) and *VE-cadherin-CreER^T2^*;*Itga9^lx/lx^* ([Figures 4I-4L](#F4){ref-type="fig"}) mice at P1, when most of the valves are fully developed, and the vessels were analysed at P7. In 4-OHT treated *VE-cadherin-CreER^T2^*;*Itga9^lx/lx^* vessels integrin-α9 expression was lost from lymphatic endothelia ([Figure 4K](#F4){ref-type="fig"}). However, the valve leaflets appeared normal ([Figures 4I and 4J](#F4){ref-type="fig"}), and integrin-α9 negative endothelial cells remained attached to the matrix core ([Figures 4I, 4K and 4L](#F4){ref-type="fig"}), suggesting that integrin-α9 is dispensable for stable adhesion of endothelial cells in fully developed valves. Together, these results suggest that integrin-α9 is required tissue-autonomously in endothelia for the development of lymphatic valve leaflets, while it is not essential for maintaining valve structure and endothelial cell adhesion in mature valves.

Integrin-α9 ligand, fibronectin-EIIIA, is expressed in the developing lymphatic valves {#S7}
--------------------------------------------------------------------------------------

To examine the function of integrin-α9 in the formation of valve leaflets we investigated the expression and localization of its ligands, including Tenascin-C (TNC), Osteopontin (OPN) and fibronectin containing the EIIIA domain (FN-EIIIA) ([@R23]; [@R47]; [@R48]) in the developing lymphatic vessels. Confocal longitudinal cross section of a valve from E18.5 mesenteric vessels revealed expression of integrin-α9 and its ligand TNC on both luminal and abluminal sides of the valve endothelial cells ([Figures S4A-S4C](#SD1){ref-type="supplementary-material"}), while no staining was seen for OPN (data not shown). Interestingly, unlike FN, which was detected in all lymphatic vessel basement membrane ([Figures S4D-S4F](#SD1){ref-type="supplementary-material"}), FN-EIIIA showed localization restricted to the valve matrix core ([Figures S4G-S4I](#SD1){ref-type="supplementary-material"}).

To gain further insight into the role of FN-EIIIA we analysed its expression during different stages of lymphatic valve development so as to determine the relationship between integrin-α9 expression and ECM deposition. At E16, prior to upregulation of integrin-α9 expression ([Figure 5A](#F5){ref-type="fig"}), Laminin-α5 was found deposited at specific sites along the vessel ([Figures 5A](#F5){ref-type="fig"}), whereas no fibrous staining for FN-EIIIA was detected (data not shown). Induction of integrin-α9 expression correlated with appearance of continuous FN-EIIIA fibers at sites of developing valves ([Figures 5B](#F5){ref-type="fig"}), which were identified by Laminin-α5 positive matrix ([Figure 5C](#F5){ref-type="fig"}) and the presence of cells expressing high levels of Prox1 ([Figure 5D](#F5){ref-type="fig"}). During initial steps of valve development FN-EIIIA and Laminin-α5 showed a similar localization ([Figure 5C](#F5){ref-type="fig"}). However, during leaflet elongation Laminin-α5 was found in the entire valve matrix core while FN-EIIIA fibers were concentrated on the free edges of the leaflets ([Figures 5E and 5E](#F5){ref-type="fig"}′). Similar to what has been reported for other tissues ([@R32]), FN-EIIIA expression was progressively down-regulated in postnatal lymphatic vasculature. While prominent FN-EIIIA fibers were detected in mesenteric lymphatic valves at P3 (data not shown), only weak staining was observed at P9 ([Figures S4J-S4L](#SD1){ref-type="supplementary-material"}) and no fibers were seen in adult valves (see [Figure 6D](#F6){ref-type="fig"}). These expression data suggest that FN-EIIIA is primarily involved during embryogenesis and that it has a role in the formation and extension of the valve leaflets.

Defective FN-EIIIA matrix assembly and valve leaflet formation in *Itga9^-/-^* mice {#S8}
-----------------------------------------------------------------------------------

We next examined valve morphogenesis in *Itga9^-/-^* embryos. X-Gal staining of mesenteric lymphatic vessels in E16 *Itga9^-/-^;Vegfr3^lz/^*^+^ embryos revealed normal vascular networks ([Figure S5A](#SD1){ref-type="supplementary-material"}). Consistent with the reduced number of valves observed in postnatal *Itga9^-/-^* vessels, at E17 the number of *Vegfr3*-lacZ positive constrictions ([Figures S5B-S5E](#SD1){ref-type="supplementary-material"}), that contained clusters of cells expressing high levels of Prox1 and FoxC2 was reduced when compared to the wild-type ([Figures S5F and S5G](#SD1){ref-type="supplementary-material"} and data not shown). In addition, staining of mutant valves for FN-EIIIA revealed only few short fibers ([Figures 5F-5G](#F5){ref-type="fig"}′). Cross section view through the valve showed a fibrous matrix in wild-type vessels ([Figure 5H](#F5){ref-type="fig"}). In contrast, the underdeveloped leaflets in *Itga9* deficient vessels displayed predominantly a disrupted punctuate and discontinuous pattern ([Figures 5I](#F5){ref-type="fig"}), suggesting that FN-EIIIA failed to assemble into continuous fibers. Taken together, the disorganized FN-EIIIA matrix in *Itga9* deficient vessels and the subsequent arrest in valve development suggest that the defect in valve formation in *Itga9^-/-^* mice is due to interaction between integrin-α9 and its specific ligand ([Figure 5J](#F5){ref-type="fig"}).

Fibronectin-EIIIA is required for normal development of lymphatic valve leaflets {#S9}
--------------------------------------------------------------------------------

To test directly if FN-EIIIA, or the other integrin-α9 binding ECM molecules, has a function in valve formation, we analyzed the lymphatic vessels in *Tnc, Opn* and *Fn-EIIIA* deficient mice ([@R10]; [@R24]; [@R29]). Both *Tnc* and *Opn* deficient mice displayed apparently normal lymphatic vasculature and lymphatic valves ([Figures S6A-S6F](#SD1){ref-type="supplementary-material"}), however, mice deficient for *Fn-EIIIA* partially recapitulated the integrin-α9 mutant phenotype. Quantification of Laminin-α5 positive valve structures in mesenteric lymphatic vessels of newborn mice showed a 1.5-fold reduction in the number of valves in *Fn-EIIIA^-/-^* mice when compared to the wild-type (p = 0.0026 (Mann-Whitney test), [Figure 6A](#F6){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}). Notably, 76% of the valves in *Fn-EIIIA^-/-^* mice displayed abnormal matrix ring appearance or underdeveloped leaflets and disorganized Laminin-α5 matrix ([Figures 6B and 6C](#F6){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}), similar to the valves observed in *Itga9* mutants. In wild-type controls at this developmental stage only a minor proportion of immature valves with rudimentary leaflets were observed, while in *Itga9^-/-^* mice approximately 90% of the valves were abnormal ([Figure 6A](#F6){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}). While lymphatic valve defects were pronounced in the *Fn-EIIIA^-/-^* mice during early postnatal life, they diminished during progression into adulthood, coinciding with when the expression of FN-EIIIA is down-regulated. In the ear skin of three weeks old wild-type animal, punctuate staining, but no FN-EIIIA fibers, were detected in the lymphatic vessels and the valves ([Figure 6D](#F6){ref-type="fig"}). At the same age the majority of the valves in *Fn-EIIIA* mutant animals had apparently normal leaflets when compared to the control ([Figures 6E and 6F](#F6){ref-type="fig"}). The mice also exhibited otherwise normal lymphatic vasculature, including vessel diameter and smooth muscle cell coverage ([Figures 6E and 6F](#F6){ref-type="fig"}). However, subcutaneous injection of FITC-dextran revealed reflux of dye from the collecting vessels, suggesting mild valve defects, and some morphologically abnormal valves in *Fn-EIIIA* deficient mice ([Figures 6G-6I](#F6){ref-type="fig"}, 4/4 mice analyzed). These results suggest that *Fn-EIIIA* deficiency leads to lymphatic valve defects during embryonic and early postnatal life.

Integrin-α9-EIIIA interaction regulates FN assembly in lymphatic endothelial cells {#S10}
----------------------------------------------------------------------------------

The defective FN matrix observed in the *Itga9^-/-^* valves prompted us to examine the possibility that integrin-α9-EIIIA interaction contributes to FN assembly in lymphatic endothelial cells (LECs), despite the previous findings suggesting that the EIIIA domain is dispensable for matrix assembly in fibroblasts ([@R43]). We therefore tested whether primary human LECs are able to assemble their endogenously produced FN, which contains the EIIIA domain ([Figure 7A](#F7){ref-type="fig"}). To avoid exogenous plasma FN lacking the EIIIA domain, the cells were grown in the presence of FN-depleted serum and fibril assembly was assessed by immunofluorescence for the EIIIA. After 24h in culture, a fibrillar FN-EIIIA network was detected on the surface of the LECs ([Figure 7A](#F7){ref-type="fig"}). Inhibition of integrin-α9 function, or integrin-α9-EIIIA interaction, using blocking antibodies against integrin-α9 (Y9A2) or EIIIA (IST-9) ([Figures 7A and 7B](#F7){ref-type="fig"}), or a blocking EIIIA peptide EDGIHEL ([@R23])(data not shown), led to a significant decrease in FN-EIIIA fibril formation. *FN-EIIIA* levels were not reduced ([Figures 7C](#F7){ref-type="fig"}), indicating that the defect was not due to impaired mRNA synthesis. A similar effect was seen when integrin-α9 expression was silenced using siRNA oligos ([Figures 7A-7D](#F7){ref-type="fig"}). In contrast, inhibition of RGD-dependent integrin interactions, which have been considered essential for FN assembly via α5β1 and αv integrins, had no effect ([Figure 7B](#F7){ref-type="fig"}), while siRNA-mediated knock-down of integrin-α5 ([Figure 7D](#F7){ref-type="fig"}) partially blocked LEC mediated FN-EIIIA assembly ([Figure 7A and 7B](#F7){ref-type="fig"}). Deoxycholate (DOC) differential solubilization assay and Western blot analysis were further used to analyse the conversion of DOC-soluble fibrils into insoluble stable matrix containing high molecular mass FN multimers. No DOC-insoluble material was associated with the LECs in which integrin-α9 expression or the integrin-α9-EIIIA interaction was blocked ([Figure 7E](#F7){ref-type="fig"}, upper panel). Instead, similar quantities of DOC-soluble FN matrices were found in all cells ([Figure 7E](#F7){ref-type="fig"}, lower panel). Consistent with the immunofluorescence data, silencing of integrin-α5 expression partially blocked the formation of DOC-insoluble FN-EIIIA matrix ([Figure 7E](#F7){ref-type="fig"}). These results suggest that although integrin-α5 cannot functionally compensate for the loss of integrin-α9, it contributes to FN fibrillogenesis in the LECs. However, the low levels of integrin-α5 detected in the developing lymphatic vessels ([Figure 7F](#F7){ref-type="fig"}) suggest that it does not play a major role during valve morphogenesis. The above results demonstrate that integrin-α9-EIIIA interaction can directly regulate FN matrix assembly, suggesting a functionally indispensable, integrin-specific mechanism for FN fibrillogenesis in the LECs.

Discussion {#S11}
==========

The present study establishes integrin-α9 as an essential regulator of the morphogenetic process controlling the formation of lymphatic valve leaflets, which allow opening and closing of the valve in response to pressure changes. This action of the valve is critical for the maintenance of unidirectional lymphatic flow and the functionality of the entire lymphatic vascular system, highlighted by the lack or insufficient function of lymphatic valves as an underlying cause of human lymphedema ([@R1]).

The leaflets of a mature valve consist of a well-defined matrix in between two sheets of lymphatic endothelial cells, which forms a strong but elastic connective tissue core ([Figure 1](#F1){ref-type="fig"}). During embryogenesis, the formation of the lymphatic valve is initiated by upregulation of FoxC2 and Prox1 transcription factors in distinct clusters of endothelial cells, which define the positions of future valves (([@R31]), see [Figure 5J](#F5){ref-type="fig"}). We found that the development of the valve leaflet is subsequently initiated by upregulation of integrin-α9 expression and deposition of ECM containing its ligand, the EIIIA splice isoform of FN. The localization of FN-EIIIA at the distal tip of the developing valve suggested its function in regulating valve leaflet elongation. However, from previous studies the precise function of FN-EIIIA has remained elusive. Despite strong expression in the angiogenic blood vessels, no vascular phenotypes were reported in *Fn-EIIIA* deficient mice ([@R3]). *In vitro* studies demonstrated that inclusion of the EIIIA segment enhanced the ability of FN to incorporate into existing matrix ([@R13]). This suggests that FN-EIIIA may participate in FN fibrillogenesis, which is a highly regulated, multistep process initiated by binding of integrins to specific sites in the FN molecule ([@R22]; [@R46]). Studies in cultured cells have revealed that generation of cytoskeletal tension through integrin-mediated cell attachment and anchoring via focal adhesions causes a change in integrin-bound FN conformation that exposes cryptic self-association sites to allow FN fiber assembly ([@R22]; [@R46]). The small GTPases, including Rho and Rac, play critical roles in cytoskeletal tension generation via regulation of actin polymerization and myosin phosphorylation ([@R6]; [@R49]). *In vivo*, tissue tension and FN fibrillogenesis can also be generated by cell-cell adhesion and cohesivity ([@R6]). The observation that FN assembly proceeded normally in *Fn-EIIIA* deficient fibroblasts ([@R43]) led to the conclusion that EIIIA domain is not required for matrix assembly ([@R22]). Instead, fibril formation in these cells was most likely mediated through binding of the major FN receptor, integrin-α5β1, to the Arg-Gly-Asp (RGD) motif located in the type III-10 module of FN ([@R9]), which has been considered the most important mechanism of FN assembly ([@R22]).

Surprisingly, we found that in lymphatic endothelial cells the integrin-α9-EIIIA interaction directly regulated FN fibril assembly, while RGD-dependent interactions appeared dispensable for matrix formation. Although the EIIIA domain has not been previously implicated in FN fibrillogenesis, other RGD-independent mechanisms for FN assembly have been observed. In fact, the requirement of the RGD motif for the formation of a functional fibrillar FN network *in vivo* was recently challenged as it was found that mice expressing FN with a non-functional RGD motif assembled an apparently normal FN matrix ([@R41]). The assembly of the RGD-deficient FN was mediated via integrin-αvβ3 binding to NGR sequence in the fifth N-terminal type I module of FN, which is converted to a high affinity binding site through deamidation ([@R41]). In addition, binding of Mn^2+^ activated integrin-α4β1 to the CS-1 site of the alternatively spliced V region was shown to promote FN assembly *in vitro* ([@R36]).

Our findings suggest that the defective FN matrix organization in *Itga9* mutant valves is a direct consequence of the lack of a specific integrin-matrix interaction and contributes to the observed defects in valve leaflet formation. In agreement, we found that a large proportion of lymphatic valves in neonatal *Fn-EIIIA* deficient mice displayed defective leaflets similar to those observed in the *Itga9* mutants. However, the absence of chylothorax and only partial recapitulation of the *Itga9^-/-^* phenotype suggest that the defect in lymphatic development in mice deficient of *Itga9* cannot be solely explained by a defect in EIIIA-containing FN matrix assembly. In particular, the observation that the valve defect in *Fn-EIIIA^-/-^* mice diminished in adulthood suggests that the animals can eventually overcome the requirement of FN-EIIIA, coinciding with when its expression is down-regulated. This may imply that during postnatal development other integrin-α9 ligand(s) become involved, or that FN fibrillogenesis can be mediated via alternative integrin-FN interactions. In agreement, we found that acute deletion of integrin-α9 postnatally in mature valves did not lead to degeneration of the leaflets within the one-week period investigated, suggesting that once the stable matrix fibrils are assembled, integrin-α9-EIIIA interaction is not required to maintain ECM organization and valve structure. However, our results do not exclude that integrin-α9-EIIIA is required for long-term maintenance of valves. Notably, although not normally present in adult tissues, FN-EIIIA is upregulated in various pathological situations, such as cancer, atherosclerosis and thrombosis ([@R29]; [@R43]; [@R44]). It is therefore likely that it is reactivated and plays a role also in adult lymphatic vessels under specific circumstances, for example during repair processes or when the vasculature is challenged by inflammation.

Why is integrin-α9 important specifically in valves? Unlike other parts of the lymphatic vasculature, which have thin or absent basement membranes, the discrete architecture of the connective tissue of a valve leaflet suggests specific requirement for highly regulated mechanism of matrix organization. Indeed, the development of a related structure, the heart valve, is known to rely on the formation of a highly organized ECM, and consequently, dysregulation of ECM, often caused by genetic defects in matrix protein structure or expression, is linked to heart valve disease ([@R2]; [@R25]). FN assembly is likely to play a key role in coordinating the formation of complex matrices as it has been shown to initiate the organization of other ECM proteins, such as collagens, and control the stability of matrix fibers ([@R18]; [@R39]). Our observations demonstrate that integrin-α9 is the predominant alpha subunit in lymphatic endothelia. Although the major FN receptor, integrin-α5, appeared to contribute to FN fibrillogenesis in the LECs *in vitro*, it was not able to functionally compensate for the loss of integrin-α9 either in cultured cells or *in vivo*. Low expression levels of integrin-α5 in the developing valves may provide one explanation for the dependency of these cells on alternative FN assembly pathways.

FN matrix assembly, as well as integrin-α9 signaling, promote adhesion-dependent cell growth and migration ([@R22]; [@R23]; [@R37]; [@R40]) and defects in these processes may therefore underlie the disrupted valve leaflet formation in *Itga9^-/-^* and *Fn-EIIIA^-/-^* mice. Although we cannot exclude a contribution of integrin-α9-mediated adhesion during the early events of valve formation, the observation that acute deletion of integrin-α9 in postnatal valves did not lead to cell detachment and degeneration of the valves argue against a role of integrin-α9 in mediating stable adhesion of valve endothelial cells *in vivo*. Furthermore, an *in vivo* BrdU incorporation assay showed that the valve endothelial cells expressing high levels of FoxC2, Prox1 and integrin-α9 do not proliferate during leaflet formation (E.B. and T.M., unpublished). These results suggest that endothelial cell adhesion and proliferation are unlikely to be controlled by integrin-α9 or involved in valve leaflet formation, respectively. Finally, the observed defect in valve leaflet elongation may be caused by failure in morphogenetic cell movements, which were shown to rely on proper organization of FN matrices in other developmental processes ([@R6]; [@R35]). Therefore, we propose that the key function of the integrin-α9-EIIIA interaction is to provide an integrin-specific mechanism of FN matrix assembly and thereby coordinate ECM organization to allow formation of a leaflet of necessary length and strength, capable of supporting valve function.

In summary, we demonstrate that integrin-α9 and its ligand, FN-EIIIA, play specific roles in lymphatic valve development and remodeling into functional leaflets. To our knowledge, the only other mouse mutants identified to-date, which show a failure of valve formation, show additional lymphatic defects; mice lacking the C-terminal PDZ binding domain of ephrinB2 display vessel hyperplasia ([@R27]) while *FoxC2* deficient mice have patterning defects ([@R31]; [@R33]). The specific valve defects observed in the *Itga9* mutant mice therefore reveal a previously undescribed morphogenetic process and provide potential insights into the development of valves in other parts of the vascular system, such as in the veins and the heart, which are likely to be regulated by similar molecular mechanisms. Lack of integrin-α9 signaling in mice results ultimately in chylothorax and postnatal death ([@R14]). Recent identification of mutations in the *ITGA9* gene in fetuses with congenital chylothorax ([@R26]) suggests conservation of the signaling pathway from mice to human, making integrin-α9 a candidate gene for primary lymphedema caused by valve defects.

Experimental Procedures {#S12}
=======================

Antibodies {#S13}
----------

The antibodies were rat antibodies to mouse PECAM-1 (MEC3.1, BD Biosciences), Tenascin-C (MTn-12, Abcam) and FoxC2 ([@R33]); rabbit antibodies to mouse Fibronectin (Millipore), Laminin-α5 ([@R34]) and LYVE-1 (Reliatch); rabbit antibodies to human Prox1 (Reliatech) and Fibronectin (Abcam); mouse antibodies to human cellular Fibronectin recognizing the EIIIA domain (([@R23]), FN-3E2, Sigma and IST-9, Abcam), hamster antibody to mouse PECAM-1, goat antibodies to mouse integrin-α9 and Osteopontin (R&D Systems) and Cy3-conjugated mouse antibody against α-smooth muscle actin (Sigma). The monoclonal hamster antibody to mouse Podoplanin (8.1.1) developed by Andrew Farr was obtained from the Developmental Studies Hybridoma Bank. Secondary antibodies conjugated to Cy2, Cy3 or Cy5 were obtained from Jackson ImmunoResearch.

Mouse lines {#S14}
-----------

*Itga9^-/-^* ([@R14]), *Itga9^lx^* ([@R37]), *Vegfr3^lz/^*^+^ ([@R5]), *Fn-EIIIA^-/-^* ([@R29]), *Tnc^-/-^* ([@R10]), *Opn^-/-^* ([@R24]), *Tie2-Cre* ([@R20]) and *Rosa26R* ([@R38]) mice have been described previously. *VE-cadherin-CreER^T2^* mice will be described elsewhere (R. Adams, unpublished). For the induction of Cre mediated recombination in newborn *VE-cadherin-CreER^T2^* mice, 4-hydroxytamoxifen (4-OHT; 2 μl of 10 mg/ml dissolved in ethanol) was injected i.p. at P1 and P2 and the vessels were analyzed at P7-8. All animal experiments were performed in accordance with UK Home Office and institutional guidelines.

Immunostaining and X-Gal staining {#S15}
---------------------------------

For whole-mount staining, the tissue was fixed in 4% paraformaldehyde (PFA), permeabilized in 0.3% Triton-X100 in PBS (PBSTx) and blocked in 5% milk or serum. Primary antibodies were added to the blocking buffer and incubated with the tissue overnight at 4°C. After washes in PBSTx, the tissue was incubated with fluorochrome-conjugated secondary antibodies in the blocking buffer for 2h at RT, followed by washing in PBSTx and mounting in Mowiol. The samples were analyzed using Zeiss LSM 510 laser scanning confocal microscope. All confocal images, except [Figures 5H, 5I](#F5){ref-type="fig"} and [S4A-S4I](#SD1){ref-type="supplementary-material"}, represent 2D projections of Z-stacks. Alternatively, biotin-conjugated secondary antibodies and ABC staining kit (Vector Laboratories) were used and the bound antibodies were visualized using diaminobenzidine (DAB) as a substrate. For histological analyses, skin biopsies were fixed in 4% PFA overnight, dehydrated and embedded in paraffin. Sections (5μm) were stained after heat-induced epitope retrieval using Tyramide Signal Amplification kit (TSA, NEN Life Sciences) and 3-Amino-9-Ethylcarbazole (AEC) as a substrate. For the visualization of lymphatic vessels in *Vegfr3^lz/^*^+^ reporter mice, the tissues were fixed with 0.2% glutaraldehyde and stained by the β-galactosidase substrate X-gal (Promega).

Visualization of lymphatic vessel function {#S16}
------------------------------------------

FITC-dextran (Sigma, 8 mg/mL in PBS) or FITC-conjugated *Lycopersicum Esculentum* lectin (Vector Laboratories, 1 mg/ml in PBS) was injected subcutaneously into an anesthetized mouse and the lymphatic vessels were analyzed by fluorescence microscopy.

Electron microscopy {#S17}
-------------------

The intestines were dissected from P5 mice and immediately fixed in 4% PFA/2.5% glutaraldehyde in 0.1M phosphate buffer pH 7.4. The samples were post fixed in reduced osmium tetroxide for 1 hour followed by 1% tannic acid in 0.05M sodium cacodylate for 45 minutes. Samples were then dehydrated through a graded series of ethanol and embedded in Araldite (Agar Scientific). Semi-thin sections were cut on a UCT ultramicrotome (Leica Microsystems UK), stained with 1% Toluidine Blue in 1% Borax and viewed under a III RS light microscope (Carl Zeiss UK) to locate the area of interest. Ultra-thin sections were cut and stained with lead citrate before being examined in a JEOL 1010 microscope and imaged with a Bioscan CCD (Gatan UK).

Cell culture {#S18}
------------

Human lymphatic endothelial cells (LEC) were isolated from primary dermal microvascular endothelial cell cultures (PromoCell) using rat antibody to human Podoplanin (NZ-1, Angiobio) and Mini/MidiMACS magnetic separation system (Miltenyi Biotech), as previously described ([@R28]). The cells were cultured on fibronectin (Sigma) coated plates in the presence of 10 ng/ml VEGF-C (R&D Systems) and used at passages 4-6. For siRNA mediated knock-down, LECs were transfected twice during 48h using calcium phosphate (Dharmacon) in DMEM, supplemented with 20% FBS, followed by recovery in Endothelial Cell Medium (PromoCell) for 24h before the cells were used for experiments. ON-TARGETplus siRNAs were obtained from Dharmacon. The following targeting sequences were used: *ITGA9*\_1: GAAGAAAGUCGUACUAUAG, *ITGA9*\_2 GUGCAGAGAUGUUUCAUGU and *ITGA5*: UCACAUCGCUCUCAACUUC. Control transfections were carried out using ON-TARGETplus siControl Non-targeting siRNA from Dharmacon.

Analysis of FN fibril assembly {#S19}
------------------------------

LECs in 5% FN-depleted serum were plated on glass coverslips. Similar results were obtained when the coverslips were coated with 0.2% gelatin (no exogenous FN) or with extracellular matrices extracted from *FN-EIIIA*^+^*^/^*^+^ ([@R29]) embryonic fibroblasts (containing small quantities of exogenous FN, all of which contains the EIIIA domain). The function-blocking antibodies (mouse anti-human integrin-α9 (Y9A2; Millipore) and EIIIA (IST-9; Abcam)) and the blocking peptides were used at a concentration of 10 μg/ml. 24 hours after plating the cells were fixed in 4% PFA and FN fibril assembly was examined using immunofluorescence. Images from five randomly chosen view fields from two independent experiments were acquired. Image processing and analysis was performed using MetaMorph Imaging software (Molecular Devices). Scaled images were thresholded and filtered so that only FN-EIIIA-specific fibers greater than 4 pixels (1.8 μm) were recorded. The total fiber length per cell was calculated by dividing the total value recorded with the number of cells present in each image. Isolation of DOC-soluble and -- insoluble matrix was done as previously described ([@R45]). Equal amounts of total protein were separated by non-reducing 5% SDS-PAGE, transferred to nitrocellulose and probed with anti-EIIIA antibody (FN-3E2).

Western blot analysis {#S20}
---------------------

The cells were lysed in Triton-X100 lysis buffer (50 mM Tris pH 7.5, 120 mM NaCl, 10% glycerol, 1% TritonX-100) supplemented with Complete Protease Inhibitors (Roche). Lysates were clarified by centrifugation and subjected to immunoprecipitation and/or Western blot analysis using standard protocols. The antibodies were mouse antibody to human integrin-α5 (GBS5; Millipore) and human integrin-α9 (Y9A2; Millipore, for IP), chicken antibody to human integrin-α9 (GenWay, for WB) and mouse antibody to human α-tubulin (TAT-1). The bound antibodies were detected using HRP-conjugated secondary antibodies (Jackson ImmunoResearch) and ECL chemiluminescence.

Relative quantitative PCR {#S21}
-------------------------

RNA from LECs was reverse transcribed using random hexamers and an avian myeloblastosis virus reverse transcriptase (Promega). cDNA was amplified by quantitative real-time PCR (ABI 7900HT) using SYBR Green PCR master mix reagent (Qiagen). Each primer was used at a concentration of 0.5 μM. Cycling conditions were as follows: step 1, 15 min at 95°C; step 2, 20 s at 94°C; step 3, 20 s at 60°C; step 4, 20 s at 72°C, with repeat from step 2 to step 4 35 times. Data from the reaction were collected and analyzed by the complementary computer software. Relative quantitations of gene expression were normalized to the endogenous control (*GAPDH*). The primers were *ITGA9*: 5′-CGGAATCATGTCTCCAACCT-3′ and 5′-TCTCTGCACCACCAGATGAG-3′, *EIIIA*: 5′-TTGATCGCCCTAAAGGACTG-3′ and 5′-ACCATCAGGTGCAGGGAATA-3′ and *GAPDH*: 5′-GAAGATGGTGATGGGATTTC-3′ and 5′-GAAGGTGAAGGTCGGAGT-3′.

Statistical analysis {#S22}
--------------------

P values were calculated using the non-parametric Mann-Whitney test, unpaired two-tailed Student T-test or χ^2^ test as indicated.
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![Expression of integrin-α9 in mature and developing lymphatic valves\
(A, B) Immunofluorescence staining of adult ear skin with antibodies against integrin-α9 (green), FoxC2 (red) and α-smooth muscle actin (α-SMA, blue). Arrow in (B) points to a luminal valve. (C-E) Development of mesenteric lymphatic vessels. Whole-mount X-Gal staining of mesenteric lymphatic vessels from *Vegfr3^lz/^*^+^ embryos. The tissues were taken from embryos at the indicated ages (E16.5-E18.5).\
(F-K) Immunofluorescence staining of developing mesenteric lymphatic vessels of E16.5 (F, G), E17.5 (H, I) and E18.5 (J, K) with antibodies against integrin-α9 (green), Prox1 (F, red) or FoxC2 (H, J, red) and LYVE-1 (F, H, J, blue). Arrowhead in (F, G) points to a blood vessel, the smooth muscle coverage of which is positive for integrin-α9 staining. Arrows point to clusters of cells expressing high levels of Prox1 and FoxC2.\
Scale bars; A, B, H-K: 50 μm, C-G: 1 mm.](nihms141065f1){#F1}

![Abnormal valves in *Itga9* deficient mice\
(A-B′) Luminal valves in chyle-filled mesenteric lymphatic vessels of wild-type (A, A′) and *Itga9* mutant mice (B, B′). Note the difference in the shape of a wild-type in comparison to a mutant valve (A′, B′, arrows in A, B) and leakage of chyle from the mutant vessels (arrowhead in B). BF = bright field.\
(C, D) PECAM-1 immunohistochemistry of P5 mesenteric vessels and luminal valves (arrow) in wild-type (C) and *Itga9^-/-^* (D) mice.\
(E) Quantification of the number of luminal valves in P5 wild-type and *Itga9^-/-^* mesenteric lymphatic vessels (mean ± s.d., n = 4 animals per genotype, 3 vessels each). Black bar = normal V-shaped valves; white bar = abnormal valves with ring appearance. \*\*\* p \< 0.0001 (Mann-Whitney test).\
(F) Schematic representation of luminal valves (arrows) in the collecting lymphatic vessels of *Itga9*^+^*^/^*^+^ and *Itga9^-/-^* mice.\
(G-J) Transmission electron micrographs of wild-type (G, I) and *Itga9^-/-^* (H, J) valves in mesenteric lymphatic vessels of P6 mice. Arrows in (G, H) point to the matrix core (red) anchored into the vessels wall, arrowheads mark the free edges of the valve leaflets. (I) shows the valve leaflet with a connective tissue core (red). Note the rudimentary (arrows in H) or absent (J) matrix core in the mutant valves and the gaps in between the two endothelial sheets (red asterisks in J).\
(K) Schematic representation of luminal valves in the *Itga9*^+^*^/^*^+^ and *Itga9^-/-^* mice. Matrix core is indicated in red.\
Scale bars; A, B: 100 μm, C, D: 50 μm, G, H: 10 μm, I, J: 1 μm.](nihms141065f2){#F2}

![Defective lymphatic drainage in *Itga9* deficient mice\
(A, B) Visualisation of dermal collecting vessels following injection of FITC-dextran into the footpads of P6 wild-type (A) and *Itga9^-/-^* mice (B). Note the presence of an abnormal vessel network (arrowheads in B) and a valve in a vessel branch point in the *Itga9* mutants (arrow in B).\
(C, D) FITC-lectin (LEL) staining of the valves in dermal lymphatic vessels following footpad injection. No valve leaflets are seen in the *Itga9* mutant (D). Arrows in (C) point to the two valve leaflets seen from the 90° angle when compared to [Figure 2A, D](#F2){ref-type="fig"}.\
(E) Schematic representation of a side view of luminal valves as visualized by FITC-LEL staining in the collecting lymphatic vessels of *Itga9*^+^*^/^*^+^ (left) and *Itga9^-/-^* (right) mice. Arrows indicate the direction of the flow.\
Scale bars; A, B: 100 μm, C, D: 50 μm.](nihms141065f3){#F3}

![Endothelial cell specific deletion of *Itga9* during development and in mature valves\
Lymphatic vessels of *Tie2-Cre;Itga9^lx/lx^* mouse (A-D), and of 4-OHT treated *Itga9^lx/^*^+^ (E-H) and *VEcad-CreER^T2^; Itga9^lx/lx^* (I-L) mice stained with antibodies against Laminin-α5 (red), integrin-α9 (green) and PECAM-1 (blue). Expression of integrin-α9 is detected in the vascular SMC (arrowhead in A, C, E, G, I, K) but is lost from the endothelial cells in *Tie2-Cre;Itga9^lx/lx^* (C) and from most endothelial cells of the valves of *VEcad-CreER^T2^; Itga9^lx/lx^* mutant animals (I, K, open arrowhead points to a single integrin-α9 expressing cell). Note the abnormal valve in *Tie2-Cre;Itga9^lx/lx^* mouse (arrow in B), which has undergone embryonic deletion of *Itga9* allele, but intact valve leaflets (arrow in J) and the attachment of LECs on the leaflets in the *VEcad-CreER^T2^; Itga9^lx/lx^* mutant (arrow in L), which has undergone postnatal deletion of *Itga9* allele, as compared to a control (arrows in F, G).\
Scale bars; A-L: 20 μm.](nihms141065f4){#F4}

![Development of lymphatic valve leaflets in wild-type and *Itga9^-/-^* mice\
(A-C) Immunofluorescence staining of developing mesenteric lymphatic vessels of E16 (A) and E17 (B, C) wild-type embryo using antibodies against Laminin-α5, integrin-α9 and FN-EIIIA (colors as indicated). The dotted lines outline the vessels.\
(D-G) Immunolabeling of lymphatic valves in wild-type (D-E′) and *Itga9^-/-^* (F-G′) mesenteric vessels for Prox1 (green) and FN-EIIIA (red; E, F; at E17) or for Laminin-α5 (red), FN-EIIIA (green) and the endothelial marker PECAM-1 (blue; E, G; at P2). The arrows in (D, E′, F, G′) point to FN-EIIIA fibers.\
(H, I) View through the opening of the valve in P0 wild-type (H) and *Itga9^-/-^* (I) vessels, labelled for FN (red) and FN-EIIIA (green). Note the punctuate localization of FN-EIIIA in the *Itga9^-/-^* valve (arrow in I) compared to the fibrous staining in the wild-type (arrow in H).\
(J) Schematic model of lymphatic valve formation. Upregulation of Prox1 and FoxC2 transcription factors (blue nuclei) in lymphatic vessels define the positions of future valves. Deposition of extracellular matrix (red) containing Laminin-α5 and FN-EIIIA and re-orientation of cells expressing high levels of Prox1 and FoxC2 perpendicular to the vessel wall is followed by upregulation of integrin-α9 (green) on the outflow side of the future valve. *Itga9^-/-^* mice (below) display defective organization of the extracellular matrix and failure of leaflet formation.\
Scale bars; A-G: 50 μm, H, I: 10 μm.](nihms141065f5){#F5}

![Abnormal lymphatic valves in mice lacking the integrin-α9 ligand, FN-EIIIA\
(A) Luminal valve numbers in newborn wild-type, *Fn-EIIIA^-/-^* and *Itga9^-/-^* mesenteric lymphatic vessels (mean ± s.d., n ≥ 4 animals per genotype, ≥ 2 vessels each, see [Suppl. Table 1](#SD1){ref-type="supplementary-material"}). The percentage of abnormal valves is indicated: \*\*\* p \< 0.0001 (χ^2^ test).\
(B, C) Visualization of lymphatic valves in P1 wild-type (B) and *Fn-EIIIA^-/-^* (C) mesenteric vessels using antibodies against Laminin-α5. Note the incomplete development of the valve as evident by lack of leaflets (arrow in C) in the *Fn-EIIIA^-/-^* vessels.\
(D) Immunofluorescence staining of three weeks old ear skin for integrin-α9 (green) and EIIIA (red).\
(E, F) Dermal lymphatic vessels in the ears of three weeks old wild-type (E) and *Fn-EIIIA^-/-^* (F) mice labeled for Laminin-α5 (green), podoplanin (blue) and α-SMA (red).\
(G-I) FITC-dextran assay in three weeks old wild-type (G) and *Fn-EIIIA^-/-^* mice (H, I). Note the reflux of dye (arrows in H) and an abnormal valve (arrow in I) in the mutant skin.\
Scale bars; B, C: 20 μm, D:50μm, E, F, I: 100 μm, G, H: 400 μm.](nihms141065f6){#F6}

![Integrin-α9-EIIIA interaction regulates FN fibril assembly in primary human lymphatic endothelial cells\
(A) FN fibrils in primary human lymphatic endothelial cells (LECs). Integrin-α9-EIIIA interaction was blocked using antibodies against EIIIA (IST-9) or integrin-α9β1 (Y9A2), or siRNA against integrin-α9 or -α5, and stained with EIIIA antibodies.\
(B) Quantification of FN fibrillogenesis in the LECs, in which integrin-α9-EIIIA interaction (IST-9, Y9A2, α9 siRNA) or integrin-α5/RGD-dependent integrin interactions (RGDSP peptide, α5 siRNA) were inhibited, in comparison to the control cells (untreated, ctrl siRNA or RGESP peptide). Data represent mean FN-EIIIA fiber length per cell (± s.d) from five randomly chosen view fields in two independent experiments. \*\*\* p\< 0.003, n.s.= non-significant, p = 0.881 (Student T-test).\
(C) qPCR of *ITGA9* and *FN-EIIIA* in human LECs. Data represent mean ± s.d. of triplicates.\
(D) siRNA mediated knock-down of integrin expression in primary human LECs. Western blot analysis of immunoprecipitated (IP) cell lysates using integrin-α9 or -α5 antibodies (upper panels). For the loading control, the total cell lysates (TCL) were blotted against α-tubulin and EIIIA.\
(E) Conversion of DOC-soluble FN fibrils into insoluble stable matrix. DOC-insoluble (upper panel) and -soluble matrix (lower panel) isolated from the LECs were separated in non-reducing SDS-PAGE and probed for EIIIA.\
(F) Immunofluorescent staining of wild type E18 mesenteric vessels using antibodies against integrin-α9 (left panel) and integrin-α5 (right panel). Note low levels of integrin-α5 expression in the valve (arrows) in comparison to strong staining in the blood vessel endothelia (arrowhead).\
Scale bar = 20 μm.](nihms141065f7){#F7}
